Griffiths CEM - Search Results

1

A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis.

Foulkes AC, Watson DS, Carr DF, Kenny JG, Slidel T, Parslew R, Pirmohamed M; PSORT Consortium; Anders S, Reynolds NJ, Griffiths CEM, Warren RB, Barnes MR. Foulkes AC, et al. Among authors: griffiths cem. J Invest Dermatol. 2019 Jan;139(1):100-107. doi: 10.1016/j.jid.2018.04.041. Epub 2018 Jul 17. J Invest Dermatol. 2019. PMID: 30030151 Free PMC article.

2

A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy.

Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. Fortune DG, et al. Br J Dermatol. 2002 Mar;146(3):458-65. doi: 10.1046/j.1365-2133.2002.04622.x. Br J Dermatol. 2002. PMID: 11952546 Clinical Trial.

3

Resetting the research agenda for psoriasis.

Chalmers RJ, Griffiths CE. Chalmers RJ, et al. J Invest Dermatol. 2003 May;120(5):ix-x. doi: 10.1046/j.1523-1747.2003.12152.x. J Invest Dermatol. 2003. PMID: 12713600 Free article. No abstract available.

4

Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset.

Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Young HS, et al. J Invest Dermatol. 2004 Jan;122(1):209-15. doi: 10.1046/j.0022-202X.2003.22107.x. J Invest Dermatol. 2004. PMID: 14962110 Free article.

5

The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis.

Allen MH, Ameen H, Veal C, Evans J, Ramrakha-Jones VS, Marsland AM, Burden AD, Griffiths CE, Trembath RC, Barker JN. Allen MH, et al. J Invest Dermatol. 2005 Jan;124(1):103-6. doi: 10.1111/j.0022-202X.2004.23511.x. J Invest Dermatol. 2005. PMID: 15654960 Free article.

6

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.

Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD; British Association of Dermatologists. Smith CH, et al. Br J Dermatol. 2005 Sep;153(3):486-97. doi: 10.1111/j.1365-2133.2005.06893.x. Br J Dermatol. 2005. PMID: 16120132 No abstract available.

7

The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.

Warren RB, Griffiths CE. Warren RB, et al. Br J Dermatol. 2005 Nov;153(5):869-73. doi: 10.1111/j.1365-2133.2005.06880.x. Br J Dermatol. 2005. PMID: 16225593 Review.

8

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.

Young HS, Summers AM, Read IR, Fairhurst DA, Plant DJ, Campalani E, Smith CH, Barker JN, Detmar MJ, Brenchley PE, Griffiths CE. Young HS, et al. J Invest Dermatol. 2006 Feb;126(2):453-9. doi: 10.1038/sj.jid.5700096. J Invest Dermatol. 2006. PMID: 16385345 Free article.

9

The role of neuropeptides in psoriasis.

Saraceno R, Kleyn CE, Terenghi G, Griffiths CE. Saraceno R, et al. Br J Dermatol. 2006 Nov;155(5):876-82. doi: 10.1111/j.1365-2133.2006.07518.x. Br J Dermatol. 2006. PMID: 17034513 Review.

10

A classification of psoriasis vulgaris according to phenotype.

Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP, Fry L. Griffiths CE, et al. Br J Dermatol. 2007 Feb;156(2):258-62. doi: 10.1111/j.1365-2133.2006.07675.x. Br J Dermatol. 2007. PMID: 17223864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

574 results

Search Page